Shots:
- FDC has launched two variants of Favipiravir under the brand names PiFLU and Favenza to treat mild to moderate COVID-19 in India. The products will be available across the country
- Both the variant will be available at $0.74 (Rs. 55) /tablet. The DCGI had earlier approved the use of Favipiravir as an off-patent, oral antiviral drug that has shown clinical recovery in COVID-19 patients with mild to moderate symptoms
- Additionally, FDC has increased the production of Enerzal and Electral, as according to ASPEN guidelines, 03 liters of fluid intake in a day (60-20ml in every 30 min) helps in speedy recovery of people who are home quarantined
Click here to read full press release/ article | Ref: FDC | Image: Business Insider
